Aspen Pharmacare Holdings Stock Net Income
| APNHFDelisted Stock | USD 12.25 0.00 0.00% |
Aspen Pharmacare Holdings fundamentals help investors to digest information that contributes to Aspen Pharmacare's financial success or failures. It also enables traders to predict the movement of Aspen Pink Sheet. The fundamental analysis module provides a way to measure Aspen Pharmacare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aspen Pharmacare pink sheet.
Aspen |
Aspen Pharmacare Holdings Company Net Income Analysis
Aspen Pharmacare's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Aspen Pharmacare Net Income | 6.49 B |
Most of Aspen Pharmacare's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspen Pharmacare Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Aspen Pharmacare Holdings reported net income of 6.49 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Aspen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspen Pharmacare's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aspen Pharmacare could also be used in its relative valuation, which is a method of valuing Aspen Pharmacare by comparing valuation metrics of similar companies.Aspen Pharmacare is currently under evaluation in net income category among its peers.
Aspen Fundamentals
| Return On Equity | 0.095 | |||
| Return On Asset | 0.0499 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 4.58 B | |||
| Shares Outstanding | 444.95 M | |||
| Shares Owned By Insiders | 19.32 % | |||
| Shares Owned By Institutions | 60.77 % | |||
| Price To Earning | 11.83 X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 38.61 B | |||
| Gross Profit | 18.29 B | |||
| EBITDA | 10.61 B | |||
| Net Income | 6.49 B | |||
| Cash And Equivalents | 7.88 B | |||
| Cash Per Share | 17.25 X | |||
| Total Debt | 105 M | |||
| Debt To Equity | 0.38 % | |||
| Current Ratio | 1.96 X | |||
| Book Value Per Share | 159.44 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.80 X | |||
| Number Of Employees | 8.58 K | |||
| Beta | 0.62 | |||
| Market Capitalization | 3.92 B | |||
| Total Asset | 111.38 B | |||
| Retained Earnings | 28.4 B | |||
| Working Capital | 16.1 B | |||
| Current Asset | 37.2 B | |||
| Current Liabilities | 21.1 B | |||
| Z Score | 22.2 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 111.38 B | |||
| Last Dividend Paid | 3.26 |
About Aspen Pharmacare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aspen Pharmacare Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aspen Pharmacare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aspen Pharmacare Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Aspen Pink Sheet
If you are still planning to invest in Aspen Pharmacare Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aspen Pharmacare's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets |